Related Experiment Videos
Rapacuronium bromide (Organon Teknika).
1Department of Anaesthesia, Perioperative Medicine & Pain Management, The Geelong Hospital, Ryrie Street, PO Box 281, Geelong, Victoria 3220, Australia. tonyp@barwonhealth.org.au
Idrugs : the Investigational Drugs Journal
|August 30, 2005
Summary
Rapacuronium bromide, a novel anesthetic, demonstrated rapid neuromuscular block and short action duration in clinical trials. This steroidal neuromuscular blocking drug showed no cardiovascular side effects, paving the way for its potential market release.
Area of Science:
- Anesthesiology
- Pharmacology
- Clinical Trials
Background:
- Rapacuronium bromide (Org-9487) is a steroidal neuromuscular blocking agent developed by Organon Teknika.
- It is an analog of vecuronium bromide, characterized by low potency and a rapid onset and short duration of action.
Purpose of the Study:
- To evaluate the efficacy and safety of rapacuronium bromide as an anesthetic agent.
- To determine the dose-dependent neuromuscular blocking effects and duration of action.
Main Methods:
- A multicenter, randomized, assessor-blind, placebo-controlled, dose-finding study was conducted.
- The study involved patients undergoing tracheal intubation.
Main Results:
- Rapacuronium bromide produced a dose-dependent neuromuscular block.
- Doses of 1.5 to 2 mg/kg facilitated rapid tracheal intubation and provided a short duration of neuromuscular blockade.
- No cardiovascular side effects were observed.
Conclusions:
- Rapacuronium bromide is a promising anesthetic agent with a favorable profile for rapid intubation and short-acting neuromuscular blockade.
- The drug's lack of cardiovascular side effects supports its potential clinical utility.